| Drug General Information |
| Drug ID |
D04JZP
|
| Former ID |
DIB015769
|
| Drug Name |
Mazapertine succinate
|
| Synonyms |
RWJ-37796
|
| Drug Type |
Small molecular drug
|
| Indication |
Psychotic disorders [ICD9: 290-299; ICD10:F20-F29]
|
Phase 2 |
[1]
|
|---|
| Company |
RW Johnson Pharmaceutical Research Institute
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C30H41N3O6
|
| Canonical SMILES |
C(=O)(N1CCCCC1)c1cc(CN2CCN(c3c(OC(C)C)cccc3)CC2)ccc1.C(<br />=O)(CCC(=O)O)O
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 1A receptor |
Target Info |
Modulator |
|
|---|
| D(2) dopamine receptor |
Target Info |
Modulator |
|
|
KEGG Pathway
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04015:Rap1 signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors. J Med Chem. 1998 Jun 4;41(12):1997-2009. |
|---|
